US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

ホーム
投資
ETF
ヨーロッパ
EU
Amundi Asset Management SAS (GOLD) 銘柄情報

Amundi Asset Management SAS (GOLD)

148.786

0.00

(0.00%)

終了 6月16日 12:30AM

Amundi Asset Management SAS (GOLD) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

148.786

( - )

買値

155.00

売値

140.00

出来高

-

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

148.786

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

0 €

発行済株式数

-

配当利回り

PER

-

1 株当たり利益 (EPS)

-

歳入

6.39M

純利益

2.76k

Amundi Physical Metals plc is a debt issuing vehicle. The company was incorporated in 2018 and is based in Dublin, Ireland. Amundi Physical Metals plc operates as a subsidiary of Cafico Trust Co Ltd. Amundi Physical Metals plc is a debt issuing vehicle. The company was incorporated in 2018 and is based in Dublin, Ireland. Amundi Physical Metals plc operates as a subsidiary of Cafico Trust Co Ltd.

セクター

-

業界

-

本社

Dublin, Ireland

設立

2026

Amundi Asset Management SAS is listed in the sector of the ユーロネクスト with ticker GOLD. The last closing price for Amundi Asset Management ... was 148.79 €. Over the last year, Amundi Asset Management ... shares have traded in a share price range of 0.00 € to 0.00 €.

Amundi Asset Management ... currently has shares in issue.

Critical Alerts for Google, Bank of New York Mellon, United Airlines, AOL, and Randgold Resources Released by Seven Summits Rese

CHICAGO, Dec. 16 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for GOOG, BK, UAUA, AOL, and GOLD. Seven Summits Strategic...

Additional Listing

GOLD FIELDS LIMITED APPLICATION FOR LISTING OF CONSIDERATION SHARES Application has been made for admission to the Official List of the London...

Statement re Strategic Partnership

Gold Fields and Fujian Zijin Mining Industry Co. Limited Announce Strategic Partnership HONG KONG, Dec. 22 -- Gold Fields Limited, through its...

Acquisition(s)

TO BUSINESS EDITOR: Gold Fields Acquires Cerro Corona Project in Peru JOHANNESBURG, South Africa, Dec. 19 -- Gold Fields Ltd. (NYSE: GFI;...

Additional Listing

GOLD FIELDS LIMITED APPLICATION FOR LISTING OF CONSIDERATION SHARES Application has been made for admission to the Official List of the London...

Correction : Further re Mvelaphanda Resources Ltd

THIS ANNOUNCEMENT IS AN AMENDED VERSION FROM THE ANNOUNCEMENT RELEASED AT 15H00. THE CORRECTION RELATES TO PARAGRAPH 7.6 WHICH NOW READS AS...

Gold Fields and Mvela details of empowerment deal

Gold Fields and Mvela announce details of structure and terms of groundbreaking empowerment deal Johannesburg, Wednesday 26 November 2003. Gold...

Further re Mvelaphanda Resources Ltd

Mvelaphanda Resources Limited Gold Fields Limited Registration number: 1980/001395/06 Registration number: 1968/004880/06 ISIN: ZAE000037610 JSE...

Gold Fields to spend A$125 million on new mill

MEDIA RELEASE GOLD FIELDS TO SPEND A$125 MILLION ON A NEW MILL AT ST IVES, WESTERN AUSTRALIA Johannesburg, 20 November 2003 - Gold Fields Limited...

Additional Listing

GOLD FIELDS LIMITED APPLICATION FOR LISTING OF CONSIDERATION SHARES Application has been made for admission to the Official List of the London...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
SHOEShoe Station Group Inc	US$ 16.85 (16,750.00%)	590.42k
CASTFreeCast Inc	US$ 3.73 (140.65%)	158.15M
CUPRCuprina Holdings Cayman Ltd	US$ 8.48 (113.60%)	48.56M
VSMEVS Media Holdings Ltd	US$ 3.25 (92.31%)	64.72M
PRFXPRF Technologies Ltd	US$ 2.4801 (82.36%)	47.33M
ELTXElicio Therapeutics Inc	US$ 4.07 (-72.59%)	8.46M
MEHAFunctional Brands Inc	US$ 0.01845 (-55.43%)	77.56M
CNTXContext Therapeutics Inc	US$ 0.6794 (-51.12%)	20.59M
NMRANeumora Therapeutics Inc	US$ 0.9177 (-48.44%)	17.74M
SNBRSleep Number Corporation	US$ 0.2202 (-43.57%)	17.1M
ADTXAditxt Inc	US$ 0.013 (2.36%)	827.76M
PAVSParanovus Entertainment Technology Ltd	US$ 0.177 (-14.90%)	671.36M
SPCXSpace Exploration Technologies Corporation	US$ 192.50 (19.60%)	256.78M
WOKWORK Medical Technology Group Ltd	US$ 0.0856 (13.68%)	199.07M
GDCGD Culture Group Ltd	US$ 0.1034 (4.44%)	190.17M

price_and_volume

price_and_volume 3分前

Gonna have to bump the A/S then...
He said recently that they are looking at another acquisition...and he will dilute with shares to get it. Agreed - I posted the same, "where's the finance coming from for acquisitions?"...

Supposed 400MM shares going to $GTVH (believe it when

StockItOut

StockItOut 4分前

WKSP Weekly chart: https://schrts.co/IIIuZpgy

CelestialSage6

CelestialSage6 5分前

I understand that Halozyme has not signed any exclusive agreements regarding treatments or indications related to Dupixent, so why is Sanofi collaborating with Alteogen?

Also, Halozyme's mdase patent is being invalidated due to Merck. Alteogen's technology is more advanced than Halozy

Wolf-man jack

Wolf-man jack 6分前

WQLF SAYS: Have Mercy WQLF ahoooooo

Q: Why hasn't CV SCIENCES been accepted in the CMS Medicare Pilot Program?

Ai Generated:

CV Sciences has not been "accepted" into the CMS Medicare Pilot Program because the pilot is a provider-led incentive, not a pro

price_and_volume

price_and_volume 8分前

What reasonable expectation is there of PPS responding?
whether management can successfully execute on the vision they have laid out. Nobody cares about "the company" or "the management" or "their vision" or your two-bit-MBA-tutorials-in-a-post.

Enough of all that garbage.

mrwrn2010

mrwrn2010 10分前

Disagree. The outcome of OxyContin litigation was unknown 9 months to a year ago. You can guess at a variety of outcomes, sure, but it’s not certain. Same thing with human trials - we don’t have positive trial results for anything in the pipeline until we have them. What passes in vitro may not pass

PEACHMAN

PEACHMAN 12分前

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177680761

IFUS STRONG

price_and_volume

price_and_volume 13分前

I get that, but that's not what I asked.

I'm not bullying you or accusing you of pumping.

You repeatedly point out what you consider to be nefarious shenanigans, so I asked: PPS hasn't effectively changed in THREE YEARS , other than a few short days 1 year ago this wee

Homework.Investwell

Homework.Investwell 20分前

2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800

Suite 800 is empty....🤔

Linda lives in Missouri now but headquarters could be moved anywhere...or will they need it?

I think we're going to find out by the end of the sum

Mdk1

Why this paper is highly interesting for Lightwave Logic (GROK)
This is a top-scored paper that strongly validates Lightwave Logic’s Perkinamine™ chromophore series 3 as a leading electro-optic material for next-generation datacenter optics.

Key Reasons Why It Matters:

janice shell

janice shell 29分前

Now that's a real head-scratcher! But shorts have to be smart, so I'd say torso and head.

gitreal

gitreal 31分前

Anyone with half a Brian can see this company is being crazy shorted!

Which half? Torso and head?

HyGro

NWBO could file an FDA application anytime but they haven't and have shown no intent to do so. Instead they are just burning more shareholder cash and if approved, will lose money on every dose because NICE will hammer the reimbursement down below Advent's costs. NWBO will lose money and collaps

US Market News

US Market News 37分前

TotalEnergies SE: Disclosure of Transactions in Own SharesJune 16, 2026 2:00 AM
Business Wire Regulatory News In accordance with the authorizations given by the shareholders’ general meeting on May 29, 2026, to trade on its shares and pursuant to applicable law on share

HyGro

Sorry, not enough. NWBO won't make any profit selling in the UK. NICE hates personalized oncology treatments and won't pay enough for NWBO to make a profit.
That's what counts. And NWBO will go under or just become Advent Contract Manufacturer. They have no cash or credit to fund any sub

biotechinvestor1

biotechinvestor1 41分前

Don’t start spazzing again, Alteogen circus clown. The Sanofi news is old.
Once Merck settles/licenses from Halozyme, Sanofi and all others will follow.
Your Alteogen stole IP from Halozyme and will pay a price for it. You can count on it.
The companies who have signed with Alte

Steady_T

Steady_T 41分前

Your theory will be put to the test after UK approval. I give it 6 months as a guess.

HyGro

What's true is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How many years are you going to wait to find out???

HyGro

What's True is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How long are you going to wait to find out???

Mdk1

Google Scholar alert - new article: "A Comparison of Plasmonic Modulator Structures in the O- and C-Band for the 400G/Lane IM/DD Era"
>>> " In ALL cases, the same electro-optic organic material, Lightwave Logic’s PerkinamineTM
chromophore series 3, was used " !
https://ieeexplor

CelestialSage6

CelestialSage6 49分前

Stop talking nonsense. Sanofi is conducting clinical trials using Alteogen's technology; what are your thoughts on this? Did you sense a crisis for Halozyme?

biotechinvestor1

biotechinvestor1 51分前

I love it when Alteogen fanboys post on this board. Nearly every time they show up, Halozyme has a run up.

DR_rugby

DR_rugby 52分前

Prophecy is coming

https://www.cnbc.com/2026/06/16/boj-rate-hike-historic-inflation.html

Japanese rates are going higher

Yen is yet to be stabilize

The great unwinding is coming soon

GLTA

BigBadWolf

BigBadWolf 59分前

Authorized Shares 1,800,000,000 06/15/2026
Outstanding Shares 1,619,034,363 06/15/2026 >5m
Restricted 480,530,670 06/15/2026 >5m
Unrestricted 1,138,503,693 06/15/2026
Held at DTC 1,011,499,104 06/15/2026 >8m

Authorized Shares 1,800,000,000 06/05/2026

4retire

4retire 1時間前

One has to question why a “cash rich” company would need to raise $20-25 billion by going to bond sales that will be in 7 tranches, ranging from 2 to 30 years. The statement is that it’s for general purposes and to redo some current debt financing.

Based on recent financials, NVDA’

Amundi Asset Management ...

Northwest Biotherapeutics (QB)

Callable Zero Coupon Not...

Nordic Waterproofing Hol...

POET Technologies

WisdomTree Commodity Sec...

SANTOS BRASIL ON

Euronext Transatlantic P...

Alothon Fund Iii

International bond 2.125...

Agf Global Equity Class ...

Leverage Shares 3x UBER ...

1.926% Sec Sus Nts 15/09...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。